Cannabis_Pic / Shutterstock.com
With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.
In the past few years there has been a burgeoning interest in the use of psychedelics for the treatment of unmet medical needs in mental health.
Globally, the psychedelics drugs market was estimated to be valued at roughly $5 billion in 2020 and is projected to grow to about $11 billion by 2027.
Accompanying the efforts to commercialise psychedelic technologies has been a steady increase in patent filings as companies and universities seek to protect their investment and maximise commercial opportunities. This article addresses patent issues related to psychedelics.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Hiller, Palo Santo Ventures, fungi, psychedelics, IP protection, LSD, MDMA, USPTO, patents,